Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.92
+0.5%		$1.70
$1.35
▼
$4.12
$13.82M0.6590,705 shs42,274 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.22
-4.4%		$0.78
$0.21
▼
$1.55
$12.33M1.62970,058 shs1.81 million shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.06
-2.8%		$1.04
$0.81
▼
$4.19
$12.32M0.821.77 million shs94,930 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-1.04%+22.44%+17.90%-48.66%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.00%-70.26%-68.62%-80.46%-80.62%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.00%+4.81%+5.83%+0.93%-50.00%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.92
+0.5%		$1.70
$1.35
▼
$4.12
$13.82M0.6590,705 shs42,274 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.22
-4.4%		$0.78
$0.21
▼
$1.55
$12.33M1.62970,058 shs1.81 million shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.06
-2.8%		$1.04
$0.81
▼
$4.19
$12.32M0.821.77 million shs94,930 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-1.04%+22.44%+17.90%-48.66%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.00%-70.26%-68.62%-80.46%-80.62%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.00%+4.81%+5.83%+0.93%-50.00%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.00
Hold$25.001,202.08% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.33
Hold$9.003,981.63% Upside
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.00
Hold$14.001,220.75% Upside
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UBX, PDSB, CMMB, and PHIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/5/2026
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$2.00 per shareN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.18 per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$1.87 per shareN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$34.50M-$0.64N/AN/AN/AN/A-708.18%-136.50%N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$8.70M-$1.29N/AN/AN/AN/A-87.41%-79.76%N/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%N/A

Latest UBX, PDSB, CMMB, and PHIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.13-$0.18-$0.05-$0.18N/AN/A
8/6/2026Q2 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.36-$0.36N/A-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
10.31
10.31
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.73
0.57
0.57
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
8.39
8.39
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95

Institutional Ownership

CompanyInstitutional Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
11.91%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8.40%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.89%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
5.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
207.20 million6.34 millionNot Optionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2055.92 million51.23 millionOptionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
1011.62 million11.51 millionNot Optionable
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-stock-crashes-nearly-50-223255215.html
Unity Biotechnology stock plunges after Nasdaq delisting notice
June 30, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/unity-biotechnology-stock-plunges-after-nasdaq-delisting-notice-93CH-3774321
Unity Biotechnology Inc News (UBX) - Investing.com
June 26, 2025  |  investing.comhttps://www.investing.com/equities/unity-biotechnology-inc-news
UBX Unity Biotechnology, Inc. - Seeking Alpha
June 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/UBX
HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)
May 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/hc-wainwright-co-downgrades-unity-biotechnology-ubx/ar-AA1FAA9z
Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities
May 18, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UBX/pressreleases/32453730/unity-biotechnology-ubx-was-downgraded-to-a-hold-rating-at-mizuho-securities/
Bay Area biotech company Unity lays off every single worker, including CEO
May 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
South San Francisco biotech company lays off entire workforce, including CEO
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/biotech-company-once-valued-at-700-million-slashes-entire-workforce/ar-AA1EdIpE
Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles
May 5, 2025  |  fiercebiotech.comF
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
May 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/01/3072287/0/en/unity-biotechnology-to-present-at-the-arvo-2025-annual-meeting.html
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25, 2025  |  ophthalmologytimes.comO
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/22/3065923/0/en/unity-biotechnology-inc-reports-first-quarter-2025-financial-results-and-business-updates.html
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-8-at-h-c-wainwright-1034514135
Unity Biotechnology price target lowered to $4 from $6 at Chardan
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-6-at-chardan-1034514054
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
March 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-announces-results-from-aspire-phase-2b-study-in-dme-1034508884
Unity reports topline outcomes from trial of diabetic macular oedema therapy
March 25, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/unity-reports-topline-outcomes-from-trial-of-diabetic-macular-oedema-therapy/ar-AA1BDWQO
UNITY Biotechnology tanks on mixed results for eye disease drug
March 25, 2025  |  thepharmaletter.comT
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
March 25, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2434950/ubx-stock-down-29-on-mixed-results-from-phase-ii-eye-disease-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2434950
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema
March 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-biotechnology-shares-drop-33-153658881.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.92 +0.01 (+0.52%)
As of 04:00 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$0.22 -0.01 (-4.38%)
As of 04:00 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$1.06 -0.03 (-2.75%)
As of 04:00 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas